Hold GlaxoSmithKline Pharmaceuticals, says Avinnash Gorakssakar

Avinnash Gorakssakar, Market Expert  told CNBC-TV18, "One can hold on to GlaxoSmithKline Pharmaceuticals because I would believe that this is one company which definitely could deliver good amount of returns over the next say one to two years. I think this is a stock which does not enjoy much liquidity but considering the fact that the pharma cycle is now slow turning around and hopefully I think the way things should pan out for CY2019 I think GlaxoSmithKline Pharmaceuticals should definitely do reasonably better."

"I think keeping 18-24 month kind of horizon one could definitely expect a decent risk reward. Maybe in the short term the stock may not go anywhere, but longer term definitely good risk reward could be made by the investor," he added.